TOP10 vaccine pharmaceutical companies have collected more than $100 billion, and the domestic market is chasing

In recent years, affected by the new crown epidemic, the global vaccine market has reached another peak
.
According to the annual report data of comprehensive pharmaceutical companies, the sales of the world's top 10 vaccine manufacturers exceeded the 100 billion dollar mark in 2021, an increase of more than 300% over the previous year, of which the new coronavirus vaccine market share accounted for 60%.

In addition to the new crown virus vaccine, virus vaccine, bacterial seedling, bacterial virus vaccine compound all showed strong growth, human papillomavirus vaccine (HPV), pneumococcal conjugate vaccine (PCV), influenza vaccine ranked in the top three, driving the rapid growth
of the vaccine market.

 

The global vaccine market has reached another peak

 

The global vaccine market in 2021 is a blue ocean
.
The new coronavirus vaccine leads the market, with steady growth in human papillomavirus vaccine, pneumonia vaccine and influenza vaccine
.
Affected by the epidemic, the public's awareness of vaccines has undergone a great change, so that the vaccination rate of type II vaccines continues to rise, comprehensive pharmaceutical company annual report data, in 2021 the world's top 10 vaccine manufacturers sales exceeded 100 billion US dollars, a year-on-year increase of more than 300%, under the competition for the research and development of new crown products, vaccines have also been pushed to the cusp, as more and more anti-new crown virus drugs are on the market, vaccines will gradually fall back to the
normal trajectory.

 

Total sales of the world's top 10 vaccine manufacturers in 2021

 

In 2021, Pfizer, Merck, Sanofi, and GSK among the world's top ten vaccine manufacturers are still old players in the field of R&D and production, while Germany's BioNTech, America's Moderna, AstraZeneca, and Johnson & Johnson are also on fire, and China's Sinovac and Zhifei also seized the opportunity
。 In 2021, among the top 5 brands in the main global new crown vaccine market, Pfizer accounted for 40.
07%, Germany's Byntec accounted for 24.
49%, the United States Moderna accounted for 19.
25%, China's Sinovac Biotech accounted for 9.
23%, and AstraZeneca accounted for 4.
36%.

According to the data, the size of China's vaccine market in 2021 will exceed 76 billion yuan, and second-class vaccines will account for 95% of the market size, with a compound annual growth rate of 29.
1%
in the past five years.

 

The proportion of sales of the world's top 10 vaccine manufacturers in 2021

 

Vaccines in public hospitals in key provinces and cities in China continue to grow

 

China's huge population base provides a broad space for the development of vaccination, especially under the influence of the new crown epidemic, the defense measures have been raised to an unprecedented height, and the public's awareness of vaccines has also increased
.

 

In recent years, the vaccine market sales of public hospitals in key provinces and cities in China

 

According to data from Minai.
com, the vaccine market in public hospitals in key provinces and cities in China has continued to grow in recent years, exceeding 500 million yuan in 2021, with a year-on-year growth rate of 28.
99%.

In fact, the public hospital vaccine market is basically 2 types of self-funded vaccines, mainly chickenpox vaccine, pneumonia vaccine, influenza vaccine, oral rotavirus live vaccine, Haemophilus influenzae type b vaccine, HPV vaccine, etc
.

 

In the first half of 2022, it still hit a new high of nearly 300 million yuan, with a growth rate of 30.
96%.

Among them, viral vaccines accounted for 88.
68%, bacterial seedlings accounted for 7.
94%, and bacterial virus vaccines accounted for 3.
38%.

The total sales of TOP6 vaccines exceeded 200 million yuan, a year-on-year increase of 46.
17%, which were human rabies vaccine, nine-valent human papillomavirus vaccine, quadrivalent human papillomavirus vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine, bivalent human papillomavirus vaccine and recombinant shingles vaccine
.

 

In the first half of 2022, the top 20 vaccine manufacturers in public hospitals in key provinces and cities in China changed compared with the same period of the previous year, and Xiamen Wantai Canghai Biotechnology jumped from 17th to 4th under the rapid growth of bivalent human papillomavirus vaccine
.
After the launch of Yuxi Watson's 13-valent pneumococcal polysaccharide conjugate vaccine, it entered the 8th place from 11th
.
Chengdu Olympiac relied on adsorbed tetanus vaccine from 13th to 11th, Liaoning Yisheng Biopharmaceutical entered the 13th place from 19th to 13th after the launch of human rabies vaccine, and Shenzhen Kangtai Biopharmaceutical and Beijing Zhifei Luzhu Biopharmaceutical advanced to the TOP20, ranking 19th and 20th respectively
.

 

The growth rate is rapid, and the sales of human papillomavirus vaccine exceed 100 million

 

With the development and marketing of human papillomavirus (HPV) vaccine, the prevention of cervical cancer has gradually attracted the attention of women, driving the growth of
the human papillomavirus vaccine market.
In 2021, the global human papillomavirus vaccine market size has approached 6 billion US dollars, a year-on-year increase of 42.
11%, and the market continues to grow
under the improvement of academic promotion and defense concepts.

 

Under the expansion of the indication of Merck nine-valent human papillomavirus vaccine, the HPV nine-valent vaccine has been expanded from 16-26 years old to 9-45 years old
.
This means that the scope of HPV vaccination in China, which is bivalent, quadrivalent and nine-valent, has been comprehensively expanded
.

 

Under the situation that the domestic HPV vaccine market gap is large, the research and development and marketing of domestic vaccines supplement this market
.
In March 2022, after China approved Yuxi Zerun Biotechnology's bivalent human papillomavirus vaccine "Wozehui", five HPV vaccines have been approved for marketing
in China.
In addition, GlaxoSmithKline's bivalent HPV vaccine "Criss", Merck's quadrivalent HPV and nine-valent HPV vaccine "Jiadaxiu", and Xiamen Wantai Canghai Biotechnology's bivalent human papillomavirus vaccine "Cinchonin"
approved on December 30, 2019.

 

In recent years, the growth rate of HPV vaccine in public hospitals in key provinces and cities in China

 

According to data from Minai.
com, the market for human papillomavirus vaccine in public hospitals in key provinces and cities in China will exceed 100 million yuan
in 2021.
Under the favorable situation of national policies, the first half of 2022 grew rapidly, with a year-on-year increase of 148.
21%.

Merck's Jiada repair nine-valent growth rate was 279.
18%, Jiadaxiu quadrivalent growth rate was 78.
46%, Xiamen Wantai Canghai Biotechnology's bivalent vaccine Cinchonin increased by 148.
21%, and GlaxoSmithKline's bivalent Xirui Shirui fell by 39.
43%.

Domestic bivalent HPV vaccine is nearly 50% cheaper than imported seedlings, and the cost performance is relatively high, thus opening up the market and shrinking GlaxoSmithKline's bivalent HPV vaccine in the domestic market
.

 

13-valent Pneumococcus conjugate vaccine increased by more than 30%

 

Data show that about 1.
6 million people die of pneumonia infectious diseases every year in the world, infants and the elderly account for the majority, especially after the outbreak of the new crown epidemic, human beings pay more attention
to pneumonia and respiratory infectious diseases.
At present, the pneumococcal polysaccharide vaccines used globally are mainly Pfizer's Peier 13, Merck's 23-valent pneumococcal polysaccharide vaccine Newmofa, and GlaxoSmithKline's 10-valent childhood pneumococcal vaccine Synflorix
.
According to the annual reports of multinational companies, the market size of the above three vaccine varieties in 2021 was 6.
628 billion US dollars
.

 

China's pneumonia vaccine market has a broad market space, Pfizer's Prevnar13 (Peier) has shown a growth trend in the past two years, Minai.
com data shows that in the first half of 2022, the year-on-year growth rate of 13-valent pneumococcal polysaccharide conjugate vaccine in public hospitals in key provinces and cities in China was 30.
49%.

The State Food and Drug Administration has approved the registration application of 13-valent pneumococcal polysaccharide conjugate vaccine from Yuxi Watson Biotechnology and Beijing Minhai Biotechnology, which means that the domestic 13-valent pneumonia conjugate vaccine has been approved for marketing
.

 

Quarterly sales of 13-valent pneumococcal polysaccharide conjugate vaccine in public hospitals in key provinces and cities in China in recent years (10,000 yuan)

 

According to data from Minai.
com, in the first half of 2022, imported seedlings accounted for 62.
87% of the 13-valent pneumococcal polysaccharide conjugate vaccine market in public hospitals in key provinces and cities in China, and domestic seedlings accounted for 37.
13%.

Domestic 13-valent pneumonia conjugate vaccine approval has a wide range of vaccination ages, and the price will be lower than that of imported products, and there will be a broader market
in the future.

 

In the domestic 23-valent pneumococcal polysaccharide vaccine occupancy occupancy vaccine occupancy occupancy vaccine occupancy vaccine occupancy drug occupancy vaccine occupancy occupancy vaccine occupancy drug occupancy vaccine occupancy drug occupancy vaccine occupancy polysaccharide vaccine occupancy polysaccharide vaccine 23 pneumococcal polysaccharide vaccine 23 pneumococcal polysaccharide vaccine 23 pneumococcal polysaccharide vaccine 23 pneumococcal polysaccharide vaccine 23 pneumococcal polysaccharide vaccine has been approved for the listing of four companies, including Chengdu Institute of Biological Products, Yuxi Watson Biotechnology, Beijing Minhai Biotechnology and Beijing Kexing Biologics under
Kangtai Biotechnology 。 In many cities in China, 65-year-old people have been vaccinated with 23-valent pneumococcal polysaccharide vaccine free of charge, on the other hand, Yuxi Watson has donated to specific groups of people nationwide through the Red Cross, charitable organizations, etc.
, so the self-funded varieties of 23-valent pneumococcal polysaccharide vaccine in public hospitals have shown a downward trend
.

 

Source: Minainet database, company announcements

 

Note: The chemical drug terminal competition pattern database of public hospitals in key provinces and cities of Minai.
com is based on the chemical drug procurement data of 20+ provinces and cities and nearly 700 sample provinces and cities public hospitals, and continuously monitors the sample provinces and cities of all chemical drug categories; The above sales are calculated
based on the average retail price of the product at the terminal.
If there is any omission, welcome to correct!